基本介紹
- 中文名：吳寶劍
- 國籍：中國
- 職業：教師
- 性別：男
科研情況,科研項目,發明專利,社會兼職,
科研情況
主要研究方向：
藥物新劑型、藥物吸收與代謝及藥代動力學。
發表論文：（* 通訊作者）
1.WuB*,DongD.(2012)Humanglutathionetransferases:structure,function,and drug dis-covery. TrendsPharmacolSci.33(12):656-668.(IF:9.3)
2.WuB*,LiS,DongD.(2013)3Dstructuresandligandspecificitiesofnuclearxenobiotic receptorsCAR,PXR,andVDR.DrugDiscovToday.18(11-12):574-81.(IF:6.6)
3.WuB*(2011)Substrateinhibitionkineticsindrugmetabolismreactions.DrugMetab Rev. 43(4):440-456.(IF:5.5)
4.DongD,WuB*,ChowD,HuM(2012)Substrateselectivityofhumancytochrome p450spredi-cted fromcrystalstructuresandinsilicomodeling.DrugMetabRev.44(2):192-208.(IF:5.5)
5.ZhouX,MaZ,DongD,WuB*,(2013)ArylamineN-acetyltransferases:AStructural Perspec-tive. BrJPharmacol.169(4):748-60.(IF:5.1)
6.WuB,WangX,ZhangS,HuM(2012)Accuratepredictionofglucuronidationof structurally diversephenolicsbyhumanUGT1A9usingcombinedexperimentaland insilicoapproaches. Pharm Res.29(6):1544-1561.(IF:4.7)（封面論文）
7.WuB,JiangW,YinT,GaoS,HuM(2012)Anewstrategytorapidlyevaluate kineticsof glucuronideeffluxbyBCRP/ABCG2.PharmRes.29(11):3199-3208.(IF:4.7)
8.WuB,XuB,HuM(2011)Regioselectiveglucuronidationofflavonolsbysixhuman UGT1A isoforms.PharmRes.28(8):1905-1918.(IF:4.7)
9.WuB,ZhangX,HuM(2011)Evaluationof3,3’,4’-trihydroxyflavoneand3,6,4’-trihydro-xyflavone(4’-O-glucuronidation)astheprobesubstratesforhepaticUGT1A1.MolPharm. 8(6): 2379-2389.(IF:4.6)
10.WuB,BasuS,MengS,WangX,HuM(2011)Regioselectivesulfationand glucuronidation ofphenolics:insightsintothestructuralbasis.CurrDrugMetab.12(9):900-916.(IF: 4.4)
11.WuB,MorrowJK,SinghR,ZhangS,HuM(2011)3D-QSARstudiesonUGT1A9-mediated3-O-glucuronidationofflavonolsusingapharmacophore-basedCOMFAmodel. JPharmacolExp Ther. 336(2):403-413.(IF:3.9)
12.WuB*,DongD,HuM,ZhangS*(2013)Quantitativepredictionofglucuronidation in humans usingtheinvitro-invivoextrapolationapproach.CurrTopMedChem.13(11):1343-52.(IF:3.7)
13.WuB,DengD,LuY,WuW(2008)Biphasicreleaseofindomethacinfrom HPMC/pectin/calcium matrixtablet:II.Influencingvariables,stabilityand pharmacokineticsindogs. EurJ Pharm Biopharm.69(1):294-302.(IF:3.8).
14.WuB,ChenZ,WeiX,SunN,LuY,WuW(2007)Biphasicreleaseof indomethacinfrom HPMC/pectin/calciummatrixtablet:I.Characterizationand mechanisticstudy.EurJ Pharm Biopharm.67(3):707-714.(IF:3.8)
15.MaZ,LiuH，WuB*(2013)Structure-baseddrugdesignofcatechol-O-methyltransferase inhibitorsforCNSdisorders.BrJClinPharmacoldoi:10. 1111/bcp.12169.(IF:3.6).
16.WuB*(2011)PharmacokineticinterplayofphaseIImetabolismandtransport: atheoretical study.JPharmSci.101(1):381-393.(IF:3.1).
17.WuB*(2012)Useofphysiologicallybasedpharmacokineticmodelstoevaluate theimpact ofintestinalhydrolysisofglucuronideonthepharmacokineticsof aglycone.JPharm Sci.101(3):1281-1301.(IF:3.1).
18.WuB,KulkarniK,BasuS,ZhangS,HuM(2011)First-passmetabolismviaUDP-glucuronosyl transferase:abarriertooralbioavailabilityofphenolics.JPharmSci. 100(9):3655-3681. (IF:3.1).
19.DongD,WuB*(2012)InsilicomodelingofUGT1A10substratesusingthe VolSurfapproach. JPharmSci.101(9):3531-3539.(IF:3.1).
20.LiJ，MaZ，JiangR，WuB*（2013）Hormone-relatedpharmacokineticvariations associated withanti-breastcancerdrugs.ExpertOpinDrugMetabToxicol.9(9):1085-95.(IF:2.9).
21.DongD,AkoR,WuB*(2012)Crystalstructuresofhumansulfotransferases: insightsinto themechanismsofactionandsubstrateselectivity.ExpertOpinDrug MetabToxicol. 8(6):635-646.(IF:2.9).
22.LuD,ZhangJ,YangZ,LiuH,LiS,WuB*,MaZ*(2013)Quantitativeanalysis of Cistan-ches HerbausingHPLC-DAD-HRMScombinedwithchemometricmethods.JSepSci.36(12):1945-52.(IF:2.6).
23.LiuW,LiuH,SunH,DongD,MaZ,WangY,WuB*(2013)MetaboliteElucidation ofthe Hsp-90 InhibitorSNX-2112UsingUltraperformanceLiquidChromatography/QuadrupoleTime-of-flightMassSpectrometry(UPLC-QTOF/MS).Xenobiotica.(已接收)(IF:2.0)
24.AkoR,DongD,WuB*(2012)3D-QSARstudiesonUDP-glucuronosyltransferase2B7 substrates usingthepharmacophoreandVolSurf approaches.Xenobiotica.42(9):891-900.(IF:2.0)
25.LiuH,MaZ,WuB*.(2013)Structure-activityrelationshipsandinsilicomodelsofP-glycoprotein(ABCB1)inhibitors.Xenobiotica.43(11):1018-26.(IF:2.0)
26.DongD,AkoR,HuM,WuB*(2012)UnderstandingSubstrateSelectivityof HumanUDP-glucur-onosyltransferasesthroughQSARmodelingandanalysisofthehomologous enzymes. Xenobiotica. 42(8):808-820.(IF:2.0)
27.WuB,ShunN,WeiX,WuW(2007)Characterizationof5-fluorouracilreleasefrom hydroxy-propyl methylcellulosecompression-coatedtablets.PharmDevTechnol. 12(2):203-210.(IF:1.3).
2.WuB*,LiS,DongD.(2013)3Dstructuresandligandspecificitiesofnuclearxenobiotic receptorsCAR,PXR,andVDR.DrugDiscovToday.18(11-12):574-81.(IF:6.6)
3.WuB*(2011)Substrateinhibitionkineticsindrugmetabolismreactions.DrugMetab Rev. 43(4):440-456.(IF:5.5)
4.DongD,WuB*,ChowD,HuM(2012)Substrateselectivityofhumancytochrome p450spredi-cted fromcrystalstructuresandinsilicomodeling.DrugMetabRev.44(2):192-208.(IF:5.5)
5.ZhouX,MaZ,DongD,WuB*,(2013)ArylamineN-acetyltransferases:AStructural Perspec-tive. BrJPharmacol.169(4):748-60.(IF:5.1)
6.WuB,WangX,ZhangS,HuM(2012)Accuratepredictionofglucuronidationof structurally diversephenolicsbyhumanUGT1A9usingcombinedexperimentaland insilicoapproaches. Pharm Res.29(6):1544-1561.(IF:4.7)（封面論文）
7.WuB,JiangW,YinT,GaoS,HuM(2012)Anewstrategytorapidlyevaluate kineticsof glucuronideeffluxbyBCRP/ABCG2.PharmRes.29(11):3199-3208.(IF:4.7)
8.WuB,XuB,HuM(2011)Regioselectiveglucuronidationofflavonolsbysixhuman UGT1A isoforms.PharmRes.28(8):1905-1918.(IF:4.7)
9.WuB,ZhangX,HuM(2011)Evaluationof3,3’,4’-trihydroxyflavoneand3,6,4’-trihydro-xyflavone(4’-O-glucuronidation)astheprobesubstratesforhepaticUGT1A1.MolPharm. 8(6): 2379-2389.(IF:4.6)
10.WuB,BasuS,MengS,WangX,HuM(2011)Regioselectivesulfationand glucuronidation ofphenolics:insightsintothestructuralbasis.CurrDrugMetab.12(9):900-916.(IF: 4.4)
11.WuB,MorrowJK,SinghR,ZhangS,HuM(2011)3D-QSARstudiesonUGT1A9-mediated3-O-glucuronidationofflavonolsusingapharmacophore-basedCOMFAmodel. JPharmacolExp Ther. 336(2):403-413.(IF:3.9)
12.WuB*,DongD,HuM,ZhangS*(2013)Quantitativepredictionofglucuronidation in humans usingtheinvitro-invivoextrapolationapproach.CurrTopMedChem.13(11):1343-52.(IF:3.7)
13.WuB,DengD,LuY,WuW(2008)Biphasicreleaseofindomethacinfrom HPMC/pectin/calcium matrixtablet:II.Influencingvariables,stabilityand pharmacokineticsindogs. EurJ Pharm Biopharm.69(1):294-302.(IF:3.8).
14.WuB,ChenZ,WeiX,SunN,LuY,WuW(2007)Biphasicreleaseof indomethacinfrom HPMC/pectin/calciummatrixtablet:I.Characterizationand mechanisticstudy.EurJ Pharm Biopharm.67(3):707-714.(IF:3.8)
15.MaZ,LiuH，WuB*(2013)Structure-baseddrugdesignofcatechol-O-methyltransferase inhibitorsforCNSdisorders.BrJClinPharmacoldoi:10. 1111/bcp.12169.(IF:3.6).
16.WuB*(2011)PharmacokineticinterplayofphaseIImetabolismandtransport: atheoretical study.JPharmSci.101(1):381-393.(IF:3.1).
17.WuB*(2012)Useofphysiologicallybasedpharmacokineticmodelstoevaluate theimpact ofintestinalhydrolysisofglucuronideonthepharmacokineticsof aglycone.JPharm Sci.101(3):1281-1301.(IF:3.1).
18.WuB,KulkarniK,BasuS,ZhangS,HuM(2011)First-passmetabolismviaUDP-glucuronosyl transferase:abarriertooralbioavailabilityofphenolics.JPharmSci. 100(9):3655-3681. (IF:3.1).
19.DongD,WuB*(2012)InsilicomodelingofUGT1A10substratesusingthe VolSurfapproach. JPharmSci.101(9):3531-3539.(IF:3.1).
20.LiJ，MaZ，JiangR，WuB*（2013）Hormone-relatedpharmacokineticvariations associated withanti-breastcancerdrugs.ExpertOpinDrugMetabToxicol.9(9):1085-95.(IF:2.9).
21.DongD,AkoR,WuB*(2012)Crystalstructuresofhumansulfotransferases: insightsinto themechanismsofactionandsubstrateselectivity.ExpertOpinDrug MetabToxicol. 8(6):635-646.(IF:2.9).
22.LuD,ZhangJ,YangZ,LiuH,LiS,WuB*,MaZ*(2013)Quantitativeanalysis of Cistan-ches HerbausingHPLC-DAD-HRMScombinedwithchemometricmethods.JSepSci.36(12):1945-52.(IF:2.6).
23.LiuW,LiuH,SunH,DongD,MaZ,WangY,WuB*(2013)MetaboliteElucidation ofthe Hsp-90 InhibitorSNX-2112UsingUltraperformanceLiquidChromatography/QuadrupoleTime-of-flightMassSpectrometry(UPLC-QTOF/MS).Xenobiotica.(已接收)(IF:2.0)
24.AkoR,DongD,WuB*(2012)3D-QSARstudiesonUDP-glucuronosyltransferase2B7 substrates usingthepharmacophoreandVolSurf approaches.Xenobiotica.42(9):891-900.(IF:2.0)
25.LiuH,MaZ,WuB*.(2013)Structure-activityrelationshipsandinsilicomodelsofP-glycoprotein(ABCB1)inhibitors.Xenobiotica.43(11):1018-26.(IF:2.0)
26.DongD,AkoR,HuM,WuB*(2012)UnderstandingSubstrateSelectivityof HumanUDP-glucur-onosyltransferasesthroughQSARmodelingandanalysisofthehomologous enzymes. Xenobiotica. 42(8):808-820.(IF:2.0)
27.WuB,ShunN,WeiX,WuW(2007)Characterizationof5-fluorouracilreleasefrom hydroxy-propyl methylcellulosecompression-coatedtablets.PharmDevTechnol. 12(2):203-210.(IF:1.3).
科研項目
1.國家自然科學基金面上項目：植物糖基轉移酶高表達工程菌減輕抗癌藥伊立替康毒性研究 （81373496）， 起止時間：2014.1-2017.12。（75萬元，主持）。
2.廣州市珠江科技新星人才計畫（30萬元，主持）。
2.廣州市珠江科技新星人才計畫（30萬元，主持）。
發明專利
1.Methodsformakingandusingdrugdetoxifyingbacteria.（美國專利申請號:61/583,711）
2.一種間苯三酚口腔崩解片及其製備方法。（專利號:200710172518.3）
3.一種用於結腸定位給藥的在體交聯包晶片。（專利號:200610029476.3）
2.一種間苯三酚口腔崩解片及其製備方法。（專利號:200710172518.3）
3.一種用於結腸定位給藥的在體交聯包晶片。（專利號:200610029476.3）
社會兼職
1.雜誌編委
JournalofPharmacologyResearch;JournalofSingleCellGenomics&Proteomics
2.美國藥學科學家協會（AAPS）會員
3.美國藥理學與實驗治療學會（ASPET）會員
4.美國OMICSGroup會員
5.SCI雜誌審稿人
MolecularPharmaceutics;BritishJournalofPharmacology;PLoSONE;Foodand Chemical Toxicology; Xenobiotica;JournalofPharmacyandPharmacology; InternationalJournal ofNanomedicine; CurrentPharmaceuticalAnalysis; Biopharmaceutics&DrugDisposition; üInternationalJournalofMolecularSciences; AnalyticalBiochemistry;CurrentMedicinal Chemistry;BioMedResearchInternational;Mini-ReviewsinMedicinalChemistry等
JournalofPharmacologyResearch;JournalofSingleCellGenomics&Proteomics
2.美國藥學科學家協會（AAPS）會員
3.美國藥理學與實驗治療學會（ASPET）會員
4.美國OMICSGroup會員
5.SCI雜誌審稿人
MolecularPharmaceutics;BritishJournalofPharmacology;PLoSONE;Foodand Chemical Toxicology; Xenobiotica;JournalofPharmacyandPharmacology; InternationalJournal ofNanomedicine; CurrentPharmaceuticalAnalysis; Biopharmaceutics&DrugDisposition; üInternationalJournalofMolecularSciences; AnalyticalBiochemistry;CurrentMedicinal Chemistry;BioMedResearchInternational;Mini-ReviewsinMedicinalChemistry等
